Skip to main content Skip to main navigation menu Skip to site footer

Temporal and severity correlation of COVID-19 with Dermatovenereological disease at Dr. Soetomo General Hospital, Surabaya, Indonesia

  • Erik Rizka Yulianggoro ,
  • Afif Nurul Hidayati ,
  • Cita Rosita Sigit Prakoeswa ,
  • Dwi Murtiastutik ,
  • Medhi Denisa Alinda ,
  • Budi Utomo ,


Link of Video Abstract:


Background: Coronavirus disease-19 (COVID-19) is an infectious disease caused by SARS-CoV-2 with various symptoms, including skin manifestations reported in patients with confirmed cases. There were several studies about the relationship between the onset of dermatovenereological manifestation and the severity of COVID-19 with dermatovenerological manifesting itself. However, there was not much research compared with dermatovenerological disease. This study aims to describe the pattern of dermatovenereological disease related to COVID-19 and find out the temporal correlation and severity of COVID-19.

Method: This study is an analytic retrospective study using consecutive sampling. The data was taken from the medical records of COVID-19 patients at the RIK RSUD Dr. Soetomo in 2021. Twenty-five patient medical records have been selected based on the inclusion and exclusion criteria. The collected data were then analyzed using the Chi-Square test in SPSS version 25.0 for Windows.

Results: From 2907 patients, dermatovenereological diseases were found in 0.86% of COVID-19 patients. The most common onset of dermatovenereological disease was before the diagnosis of COVID-19 (65.7%); the results of this study showed that there was no relationship between dermatovenereological disease and the onset of skin symptoms (p>0.05). There was a relationship between dermatovenereological disease pemphigus foliaceus and varicella and the severity of COVID-19 medium(p<0.05).

Conclusion: Various dermatovenereological diseases can follow the symptoms of COVID-19 and may precede systemic symptoms. Most studies failed to report any correlation between the onset and severity of COVID-19 and dermatovenereological disease. Understanding and classifying dermatovenereological disease in COVID-19 patients is crucial.


  1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et. al. Clinical characteristics of coronavirus disease 2019 in china. N Engl J Med. 2020;382(18):1708-1720.
  2. Recalcati S. Cutaneous manifestations in Covid-19: A first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213.
  3. Galvan CC, Catala A, Carretero HG, Rodriguez-Jimenez P, Fernandez-Nieto D, Rodriguez-Villa LA, et al. Classification of the cutaneous manifestations of covid-19: A rapid prospective nationwide consensus study in spain with 375 cases. Br J Dermatol. 2020;183(1):71-77.
  4. Jamshidi P, Hajikhani B, Mirsaeidi M, Vahidnezhad H, Dadashi M, Nasiri MJ. Skin manifestations in covid-19 patients: Are they indicators for disease severity? A systematic review. Front Med (Lausanne). 2021;8(634208):634208.
  5. Daneshgaran G, Dubin DP, Gould DJ. Cutaneous manifestations of covid-19: An evidence-based review. Am J Clin Dermatol. 2020;21(5):627-639.
  6. Herawati S, Kandarini Y, Mulyantari NK, Prabawa IPY. Correlation of Neutrophil to Lymphocyte Ratio with Interleukin-10 in Diagnosis and Monitoring of Coronavirus Disease-19 Patients. Open Access Macedonian Journal of Medical Sciences. 2022;10(B):63-66.
  7. Sanchez-Flores X, Huynh T, Huang JT. Covid-19 skin manifestations: an update. Curr Opin Pediatr. 2021;33(4):380-386.
  8. Patrick MT, Zhang H, Wasikowski R, Prens EP, Weidinger S, Gudjonsson JE, et al. Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. J Allergy Clin Immunol. 2021;147(3):857-869.e7.
  9. Novak N, Peng W, Naegeli MC, Galvan C, Kolm-Djamei I, Brüggen C, et al. SARS-CoV-2, COVID-19, skin and immunology - What do we know so far?. Allergy. 2021;76(3):698-713.
  10. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with covid-19 in Indonesia. Journal of Community Empowerment for Health. 2020;3(2):77-77.
  11. Niu S, Tian S, Lou J, Kang X, Zhang L, Lian H, et. al. Clinical characteristics of older patients infected with covid-19: A descriptive study. Arch Gerontol Geriatr. 2020;89(104058):104058.
  12. Giefing-Kroll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14(3):309-321.
  13. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE et al. Factors associated with covid-19-related death using opensafely. Nature. 2020;584(7821):430-436.
  14. Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of icu admission and poor short-term outcome. J Clin Virol. 2020;127(1):104354.
  15. Cancarevic I, Malik BH. SARS-CoV-2 (COVID 19) infection in hypertensive patients and in patients with cardiac disease. Cureus. 2020;12(6):e8557.
  16. Kulkarni S, Jenner BL, Wilkinson I. COVID-19 and hypertension. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320927851.
  17. Giavedoni P, Podlipnik S, Pericas JM, Fuertes de Vega I, Garcia-Herrera A, Alos L, et al. Skin manifestations in COVID-19: Prevalence and relationship with disease severity. J Clin Med. 2020;9(10):1-12.
  18. Lee DS, Mirmirani P, McCleskey PE, Mehrpouya M, Gorouhi F. Cutaneous manifestations of covid-19: A systematic review and analysis of individual patient-level data. Dermatol Online J. 2020;26(12):13030-13038.
  19. Kutlu Ö, Metin A. Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatologic Therapy. 2020;33(40:e13509.
  20. Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med. 2001;7(12):1320-1326.
  21. Fernandez-Nieto D, Ortega-Quijano D, Jimenez-Cauhe J, Burgos- Blasco P, de Perosanz-Lobo D, Suarez-Valle A, et al. Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital. Clin Exp Dermatol. 2020;45(7):872–875.
  22. Hovav AH. Mucosal and skin langerhans cells—nurture calls. Trends Immunol. 2018;39(10):788-800.
  23. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727-732.
  24. Prasad A. Local ımmunity concept in the context of the novel corona viral ınfection: a consideration. Asian J Immunol. 2020;3(2):16-25.
  25. Heinen MP, Cambier L, Antoine N, Gabriel A, Gillet L, Bureau F, et al. Th1 and Th17 immune responses act complementarily to optimally control superficial dermatophytosis. J Invest Dermatol. 2019;139(3):626-637.
  26. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that vitamin D supplementation could reduce the risk of ınfluenza and COVID-19 ınfections and deaths. Nutrients. 2020;12(4):988.
  27. Mahé A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with coronavirus disease 2019? J Eur Acad Dermatol Venereol. 2020;34(6):e246–247.
  28. Najarian DJ. Morbilliform exanthem associated with COVID-19. JAAD Case Rep. 2020;6(6):493.
  29. Joob B, Wiwanitkit V. Hemorrhagic problem among the patients with COVID-19: clinical summary of 41 thai infected patients. Clin Appl Thromb Hemost. 2020;26(1):1076029620918308.
  30. Kasperkiewicz M. COVID-19 outbreak and autoimmune bullous diseases: a systematic review of published cases. J Am Acad Dermatol. 2021;84(2):563–568.
  31. Joly P. French study group on autoimmune bullous skin diseases, and the French network of rare diseases in dermatology (FIMARAD). Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: a nationwide study. J Am Acad Dermatol. 2022;86(2):494–497.
  32. Kridin K, Schonmann Y, Weinstein O, Schmidt E, Ludwig RJ, Cohen AD. The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: a population-based cohort study. J Am Acad Dermatol. 2021;85(1):79–87.
  33. Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol. 2020;34(1):e306–307.

How to Cite

Yulianggoro, E. R., Hidayati, A. N., Prakoeswa, C. R. S., Murtiastutik, D., Alinda, M. D., & Utomo, B. (2024). Temporal and severity correlation of COVID-19 with Dermatovenereological disease at Dr. Soetomo General Hospital, Surabaya, Indonesia. Bali Medical Journal, 13(1), 410–416.




Search Panel

Erik Rizka Yulianggoro
Google Scholar
BMJ Journal

Afif Nurul Hidayati
Google Scholar
BMJ Journal

Cita Rosita Sigit Prakoeswa
Google Scholar
BMJ Journal

Dwi Murtiastutik
Google Scholar
BMJ Journal

Medhi Denisa Alinda
Google Scholar
BMJ Journal

Budi Utomo
Google Scholar
BMJ Journal